Atomoxetine
Atomoxetine, Strattera (atomoxetine) is a small molecule pharmaceutical. Atomoxetine was first approved as Strattera on 2002-11-26. It is used to treat attention deficit disorder with hyperactivity in the USA. The pharmaceutical is active against sodium-dependent noradrenaline transporter. In addition, it is known to target sodium-dependent serotonin transporter and sodium-dependent dopamine transporter.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
Atomoxetine, Strattera (discontinued: Strattera)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| atomoxetine | ANDA | 2024-10-25 |
| atomoxetine hydrochloride | ANDA | 2024-09-18 |
| strattera | New Drug Application | 2022-01-06 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| attention deficit disorder with hyperactivity | EFO_0003888 | D001289 | F90 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
213 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | 3 | 16 | 27 | 46 | 27 | 117 |
| Hyperkinesis | D006948 | HP_0000752 | — | 1 | 12 | 26 | 34 | 21 | 93 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | 6 | 13 | 1 | 1 | — | 15 |
| Sleep apnea syndromes | D012891 | HP_0010535 | G47.3 | 3 | 9 | 1 | 1 | — | 11 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 3 | 1 | 4 | 1 | 9 |
| Apnea | D001049 | HP_0002104 | R06.81 | 2 | 7 | — | 1 | — | 8 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | 2 | — | 2 | 3 | 7 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | 1 | 1 | 2 | 1 | 6 |
| Dyslexia | D004410 | EFO_0005424 | F81.0 | — | — | — | 5 | — | 5 |
| Hypotension | D007022 | EFO_0005251 | I95 | 1 | 1 | — | 1 | 1 | 4 |
Show 26 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | 1 | 3 | 1 | — | — | 5 |
| Vasovagal syncope | D019462 | — | R55 | — | 1 | 1 | — | — | 2 |
| Syncope | D013575 | HP_0012668 | G90.01 | — | 1 | 1 | — | — | 2 |
| Fetal alcohol spectrum disorders | D063647 | — | Q86.0 | 1 | — | 1 | — | — | 2 |
| Neoplasms | D009369 | — | C80 | — | — | 1 | — | — | 1 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | 1 | — | — | 1 |
| Psychiatry | D011570 | — | — | — | — | 1 | — | — | 1 |
| Gastrointestinal microbiome | D000069196 | — | — | — | — | 1 | — | — | 1 |
| Probiotics | D019936 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cocaine-related disorders | D019970 | — | F14 | 2 | 2 | — | — | 2 | 6 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | 2 | — | — | 2 | 4 |
| Pure autonomic failure | D054970 | — | — | 1 | 1 | — | — | 1 | 3 |
| Cognition disorders | D003072 | — | — | — | 1 | — | — | 2 | 3 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 1 | — | — | 1 | 2 |
| Orthostatic intolerance | D054971 | — | — | 2 | 1 | — | — | — | 2 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | 2 | — | — | — | 2 |
| Tobacco use disorder | D014029 | — | F17 | 1 | 1 | — | — | 1 | 2 |
| Memory disorders | D008569 | — | — | — | 2 | — | — | — | 2 |
| Tachycardia | D013610 | HP_0001649 | R00.0 | 1 | 1 | — | — | — | 1 |
Show 10 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Wounds and injuries | D014947 | — | T14.8 | 1 | — | — | — | 1 | 2 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | 1 | — | — | — | — | 1 |
| Alcohol-induced disorders | D020751 | — | — | 1 | — | — | — | — | 1 |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | 1 | — | — | — | — | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | — | — | — | — | 1 |
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | 1 | — | — | — | — | 1 |
| Primary dysautonomias | D054969 | — | — | 1 | — | — | — | — | 1 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 2 | 2 |
| Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
| Anorexia | D000855 | HP_0002039 | R63.0 | — | — | — | — | 1 | 1 |
| Anorexia nervosa | D000856 | EFO_0004215 | F50.0 | — | — | — | — | 1 | 1 |
| Shy-drager syndrome | D012791 | EFO_1001050 | — | — | — | — | — | 1 | 1 |
| Multiple system atrophy | D019578 | — | — | — | — | — | — | 1 | 1 |
| Parkinsonian disorders | D020734 | HP_0001300 | G20.C | — | — | — | — | 1 | 1 |
| Patient dropouts | D010352 | — | — | — | — | — | — | 1 | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
| Transient ischemic attack | D002546 | EFO_0003764 | G45.9 | — | — | — | — | 1 | 1 |
Show 10 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Atomoxetine |
| INN | atomoxetine |
| Description | Atomoxetine is a secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents. It has a role as an adrenergic uptake inhibitor, an antidepressant, a xenobiotic and an environmental contaminant. It is an aromatic ether, a secondary amino compound and a member of toluenes. |
| Classification | Small molecule |
| Drug class | antidepressants (fluoxetine type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CNCC[C@@H](Oc1ccccc1C)c1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 83015-26-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL641 |
| ChEBI ID | 127342 |
| PubChem CID | 54841 |
| DrugBank | DB00289 |
| UNII ID | ASW034S0B8 (ChemIDplus, GSRS) |
Target
Agency Approved
SLC6A2
SLC6A2
Organism
Homo sapiens
Gene name
SLC6A2
Gene synonyms
NAT1, NET1, SLC6A5
NCBI Gene ID
Protein name
sodium-dependent noradrenaline transporter
Protein synonyms
NET, neurotransmitter transporter, Norepinephrine transporter, solute carrier family 6 (neurotransmitter transporter), member 2, solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2, Solute carrier family 6 member 2, solute carrier family 6 member 5
Uniprot ID
Mouse ortholog
Slc6a2 (20538)
sodium-dependent noradrenaline transporter (Q6QU62)
Alternate
SLC6A4
SLC6A4
SLC6A3
SLC6A3
Organism
Homo sapiens
Gene name
SLC6A4
Gene synonyms
HTT, SERT
NCBI Gene ID
Protein name
sodium-dependent serotonin transporter
Protein synonyms
5-hydroxytryptamine (serotonin) transporter, 5HT transporter, 5HTT, Na+/Cl- dependent serotonin transporter, serotonin transporter 1, solute carrier family 6 (neurotransmitter transporter), member 4, solute carrier family 6 (neurotransmitter transporter, serotonin), member 4, Solute carrier family 6 member 4
Uniprot ID
Mouse ortholog
Slc6a4 (15567)
sodium-dependent serotonin transporter (Q60857)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Strattera – Eli Lilly
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Atomoxetine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,901 documents
View more details
Safety
Black-box Warning
Black-box warning for: Atomoxetine, Atomoxetine hydrochloride, Strattera
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
21,997 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use